Tesofensine // The Brain Switch
A triple monoamine reuptake inhibitor that attacks obesity through the brain — blocking reuptake of serotonin, dopamine, and norepinephrine simultaneously. Phase 2 data showed 12.8% body weight loss at the 1mg dose over just 24 weeks. Originally developed for Alzheimer's and Parkinson's, the weight loss was a powerful 'side effect' that redirected its development.
Appetite control through the brain.
Tesofensine works entirely through the brain — simultaneously increasing serotonin (satiety), dopamine (reward/motivation), and norepinephrine (thermogenesis/energy). Potent appetite suppression combined with increased energy expenditure. But this CNS activity also explains the cardiovascular monitoring requirements.
Start low. Monitor everything.
Tesofensine has a 9-day half-life. It takes ~2 weeks to reach steady-state, and effects persist nearly two weeks after the last dose. Weekly BP and HR monitoring is non-negotiable.
The LIGHT study — accidental obesity drug.
Tesofensine's origin is one of pharmacology's best pivots. Developed for Parkinson's/Alzheimer's, Phase 2 revealed dramatic weight loss. The LIGHT study showed 12.8% body weight reduction at 1mg over just 24 weeks — rivaling early GLP-1 data on a faster timeline.
The 1mg dose was abandoned for cardiovascular effects. Development shifted to 0.5mg and the Tesomet combination (tesofensine + metoprolol beta-blocker). The 9-day half-life means commitment — effects don't clear for nearly two weeks after the last dose.
How it stacks against the competition.
| Compound | Receptors | Weight Loss | Half-Life | FDA Status |
|---|---|---|---|---|
| Tesofensine | Triple Monoamine RI | ~12.8% | ~9 days | Phase 3 |
| Semaglutide | GLP-1 | ~15–17% | ~7 days | FDA Approved |
| Tirzepatide | GLP-1 + GIP | ~20–26% | ~5 days | FDA Approved |
| Contrave | Bupropion/Naltrexone | ~5–8% | ~21 hrs | FDA Approved |
| Phentermine | Sympathomimetic | ~5–10% | ~20 hrs | FDA Approved |
What to watch for.
Tesofensine's side effect profile requires careful monitoring. Cardiovascular monitoring is the defining requirement. Heart rate and blood pressure must be checked weekly.
- Elevated HR and BP (DOSE DEPENDENT — primary concern)
- Dry mouth (very common)
- Insomnia (take morning only)
- Constipation
- Dizziness and headache
- Potential mood changes
- Contraindicated: uncontrolled hypertension, CV disease, anxiety, MAOIs
- 9-day half-life: effects persist ~2 weeks after stopping
- BP and HR (WEEKLY — non-negotiable)
- ECG at baseline (recommended)
- CBC and CMP
- Lipid panel
- Cortisol
- Thyroid panel
- Liver enzymes
- DO NOT combine with SSRIs, SNRIs, MAOIs, or stimulants
- Can combine with GLP-1 agonists for dual-pathway
- Fragment 176-191 or AOD-9604 for lipolysis
- 5-Amino-1MQ for NNMT (no monoamine overlap)
- Avoid caffeine and pre-workouts
- Controlled substance in some jurisdictions
- Room temperature
- Protect from moisture and light
- Pharma-grade COA required
- No reconstitution (oral)
- Ensure no adulterants
- Controlled substance in some regions
Compounds that complement Tesofensine.
Tesofensine's monoamine mechanism is independent from GLP-1, GH, and NNMT pathways — but its stimulant properties demand caution. Never combine with other stimulants, SSRIs, or MAOIs.
Powerful — but demands respect.
Tesofensine is one of the most effective anti-obesity compounds ever tested. But that power comes with real cardiovascular risk — elevated HR and BP forced the dose reduction from 1mg to 0.5mg. Start at 250mcg, monitor BP and HR weekly without exception, morning only, avoid all stimulants, and do not use with CV history or anxiety disorders. The 9-day half-life means you're committed once you start. Under proper monitoring, it's potent. Without monitoring, it's not worth the risk.
Our free 50-page Protocol Guide includes the complete Metabolic Fat Loss Stack with Tesofensine — titration schedules, stacking recommendations, blood work panels, and tracking templates.